{"id":"W2172257129","doi":"10.1016/s0140-6736(05)67566-6","title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","year":2005,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1045,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University; Probity Medical Research","funders":"","keywords":"Infliximab; Psoriasis; Medicine; Psoriasis Area and Severity Index; Placebo; Internal medicine; Gastroenterology; Clinical endpoint; Dermatology; Surgery; Randomized controlled trial; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06806402176190217,"score_gpt":0.3177268351608078,"score_spread":0.2496628133989056,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}